AAM and Biosimilars Council Statement on ACA Ruling in California v. Texas | Association for Accessible Medicines
AAM All Access Podcast - Featuring AAM CEO Dan Leonard and leaders in the generics and biosimilars industry.

AAM and Biosimilars Council Statement on ACA Ruling in California v. Texas

WASHINGTON DC (June 17, 2021) – AAM and its Biosimilars Council welcome today’s decision by the U.S. Supreme Court in California v. Texas that ensures America’s patients and taxpayers can continue to benefit from biosimilar access and competition in the marketplace that is made possible by the Affordable Care Act’s inclusion of a biosimilar pathway.

View the AAM Amicus Brief on the ACA.

 

MEDIA CONTACT:
Rachel Schwartz
202.249.7147 

 

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.